SOURCE: CannaPharmaRx, Inc.

CannaPharmaRx, Inc. Logo

January 29, 2015 08:58 ET

CannaPharmaRx Teams Up With The Catalyst Agency to Build and Introduce CMR, a Longitudinal Cannabinoid Medicines Registry Database

CARNEYS POINT, NJ--(Marketwired - January 29, 2015) - CannaPharmaRx, Inc. (OTCQB: GDHC), the New Jersey-based pharmaceutical company, is launching its proprietary Cannabinoid Medicines Registry(SM) program (CMR).

The need for accurate, reliable and up to date scientific information on the use and effectiveness of Cannabinoid Based Medicines (CBM) has been desired for years. Since its inception CannaPharmaRx has been developing a professional registry to assert its leadership in knowledge management in this sector of healthcare. 

"The release of the CMR, in the first quarter of 2015, is for initial beta site testing and enhancements. Following in-service tests, CMR in its early life-cycle will provide CannaPharmaRx real-time data in helping identify specific endocannabinoids for ultimate commercialization in global markets as a competitive advantage," said Jim Smeeding, Executive Vice President, Professional Services.

CannaPharmaRx believes our proprietary registry as it grows in patient volume will offer to healthcare providers, payers and patients the ability to help make decisions on selecting and managing cannabinoid-based pharmacological treatments and related evidence-based outcomes. 

The CannaPharmaRx real world evidence meta-registry, CMR, when fully launched will provide a longitudinal data compendium for product usage, clinical management and outcomes. These data will be of great value to patients, caregivers as well as governmental bodies seeking to identify diseases that will benefit from the use of cannabinoid-based medicines.

"We are excited to help develop the Cannabinoid Medicines Registry with CannaPharmaRx through our health information technology portal and we see their patient registry as a distinct advantage for prospective clinical decisions based on real-time data as it is collected," said Steffan Perry, Chief Technology Officer, the Catalyst Agency.

The ultimate goal of the CannaPharmaRx CMR is to enable healthcare providers the opportunity to track and monitor their patients on CBM's, provide real-world data feedback to pharmacists and payers and help patients improve their adherence, compliance and persistency. Patient feedback tools, benchmarking and progress dashboards with easy input from personal devices will assist in differentiating the CannaPharmaRx registry as well as augmenting patient engagement.

About CannaPharmaRx
Our purpose is to innovate to bring cannabinoid-based therapies to market that improve patients' lives. R&D is at the heart of our mission as we work to transform advanced science and technologies into the therapies that matter most. Our executive management team has over 100 years of combined pharmaceutical industry experience developing and marketing prescription products. 

About The Catalyst Agency
Our focus is creating custom & compliant software solutions for the medical industry. We specialize in custom software development, software integration, mobile application development, and other web development. The Catalyst Agency focuses on delivering real business value by educating our clients on the latest technologies and strategies that improve business operations, increasing efficiency and reducing cost. Catalyst provides complex and stable solutions that are customers demand. 

Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend," among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. CannaPharmaRx does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's private placement agreement and Form 10-Q as of September 30, 2014 (Unaudited) and other periodic reports filed with the Securities and Exchange Commission.

Contact Information